Biomaterial Database

Human papillomavirus testing for precancerous lesions of the cervix. 2007

Fidel A Valea

Duke University Medical Center, Durham, NC 27710, USA. valea001@mc.duke.edu

As new technologies are introduced that increase the sensitivity of detecting patients at risk and the incidence of cervical cancer continues to decrease in the US, annual screening for this disease may actually be overscreening. It has been shown that the screening interval can safely be increased to every 2 years if liquid-based testing is performed with reflex HPV testing in patients under 30 and can be increased to every three years in patients over the age of 30 if they are done together and both are negative.13,14 As we move into the age of risk stratification as a screening tool with HPV testing and liquid-based screening, it is imperative that the aforementioned recommendations are followed in order to keep the costs of screening at a minimum. Unfortunately, despite data confirming its safety and efficacy, many patients are unconvinced. The overwhelming respondents in one series would still seek to obtain annual screening. In order to complete the paradigm shift in the screening for cervical cancer using the current technologies, more education will be required of the public and health care community to understand and accept the differences, most notably the increased screening interval. The true effects of the HPV vaccine will not be known for some time. Therefore, appropriate screening is still imperative even for those vaccinated because it does not offer complete protection from other strains of the HPV virus.

UI	MeSH Term	Description	Entries
D008403	Mass Screening	Organized periodic procedures performed on large groups of people for the purpose of detecting disease.	Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D011230	Precancerous Conditions	Pathological conditions that tend eventually to become malignant.	Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D002583	Uterine Cervical Neoplasms	Tumors or cancer of the UTERINE CERVIX.	Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D004279	DNA, Viral	Deoxyribonucleic acid that makes up the genetic material of viruses.	Viral DNA
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D052685	Alphapapillomavirus	A genus of DNA viruses in the family PAPILLOMAVIRIDAE. They preferentially infect the anogenital and ORAL MUCOSA in humans and primates, causing both malignant and benign neoplasms. Cutaneous lesions are also seen.	Alphapapillomaviruses
D053918	Papillomavirus Vaccines	Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.	HPV Vaccine,Human Papilloma Virus Vaccine,Human Papillomavirus Vaccine,Human Papillomavirus Vaccines,Papillomavirus Vaccine,HPV Vaccines,Human Papilloma Virus Vaccines,Papillomavirus Vaccine, Human,Papillomavirus Vaccines, Human,Vaccine, HPV,Vaccine, Human Papillomavirus,Vaccine, Papillomavirus,Vaccines, Human Papillomavirus,Vaccines, Papillomavirus
D018570	Risk Assessment	The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)	Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments
D027383	Papillomaviridae	A family of small, non-enveloped DNA viruses infecting birds and most mammals, especially humans. They are grouped into multiple genera, but the viruses are highly host-species specific and tissue-restricted. They are commonly divided into hundreds of papillomavirus "types", each with specific gene function and gene control regions, despite sequence homology. Human papillomaviruses are found in the genera ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; GAMMAPAPILLOMAVIRUS; and MUPAPILLOMAVIRUS.